Neurocrine Biosciences, Inc. reaffirmed sales guidance for the full year of 2024. For the year, company expects INGREZZA Net Product Sales of $2,100 million to $2,200 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
140.5 USD | +0.77% | -0.05% | +6.62% |
May. 28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
May. 28 | Neurocrine founder-CEO Gorman to retire in October | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.62% | 14.14B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-0.73% | 21.83B | |
-10.37% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+17.53% | 10.71B | |
-30.73% | 7.6B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024